Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Immunology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Ulcerative Colitis Clinical Trials

A listing of Ulcerative Colitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (11) clinical trials

This is a Phase 1b multicenter, randomized, double-blind, placebo-controlled multiple dose study designed to evaluate the safety and tolerability of SER-287, and to evaluate the microbiome alterations and pharmacodynamics associated with 2 dosing regimens of SER-287 in adult subjects with mild-to-moderate ulcerative colitis (UC).


TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC. The relative bioavailability of tofacitinib released from TD-3504 compared to co-administered oral heavy-labeled tofacitinib (15N2-tofacitinib) will also be evaluated.


A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs) Participants With Ulcerative Colitis (UC) and Participants With Crohn's Disease (CD)

This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A. The study will consist of a repeat dose escalation in HVs, in participants with UC, and in participants with CD across multiple sites.


Low Dose IL-2 for Ulcerative Colitis

Interleukin-2 (IL-2) is a T cell growth factor. IL-2 is currently licensed for the treatment of metastatic renal cell carcinoma and metastatic melanoma, where it promotes the expansion of anti-cancer cytotoxic T cells and natural killer (NK) cells. However at low doses (100-times lower than those used in cancer therapy), ...


The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis

The enteric microbiota is now accepted as an important etiologic factor in the pathogenesis of human Inflammatory Bowel Disease (IBD) and immune-mediated chronic experimental intestinal inflammation, with ample data to implicate the microbiome as a main factor in the occurrence of IBD. This can be inferred from animals in germ-free ...


Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

This is a prospective open-label, randomized trial for the use of Fecal Microbiota Transplantation (FMT) for the treatment of Ulcerative Colitis (UC), in combination with or without antibiotic pretreatment. This trial involves 11 study visits at UCSF in San Francisco, CA. The routes of administration will be via colonoscopy for ...


ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

This multi-center randomized, double-blind, placebo-controlled study will evaluate the safety of ABI-M201 and its effects on disease activity measures in men and women with mildly-to-moderately active UC and ongoing treatment with mesalamine. The study will consist of 2 sequential, non-overlapping participant cohorts, separated by intervening interim analysis (IA). Both cohorts ...


GB004 in Adult Subjects With Active Ulcerative Colitis

The safety, tolerability, pharmacokinetics, and pharmacodynamics of GB004 will be explored in a Phase 1b randomized controlled trial in adults subjects with active ulcerative colitis (UC). Subjects will be evaluated based on incidence of AEs, laboratory parameters, GB004 serum and colonic tissue concentrations, and changes in the signs and symptoms ...


Double-Blinded Placebo-Controlled Phase 1b Study for Safety PK Efficacy PD of RO7049665 in Patients With Ulcerative Colitis (UC)

The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in participants with active ulcerative colitis.


Nivolumab in Treating Patients With Autoimmune Disorders or Advanced Metastatic or Unresectable Cancer

PRIMARY OBJECTIVES: I. To assess the overall safety, including the incidence of dose-limiting toxicity (DLT), and other toxicities associated with the use of the anti-programmed death 1 (PD-1) antibody nivolumab in patients with varying severity of dermatomyositis (DM)/systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease ...